	US 12,290,561 B2
	Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same
Hildegund C J Ertl, Villanova, PA (US); and Colin Stephen Magowan, Bishop, CA (US)
Assigned to Virion Therapeutics, LLC, Newark, DE (US); and The Wistar Institute, Philadelphia, PA (US)
Filed by Virion Therapeutics, LLC, Newark, DE (US); and The Wistar Institute, Philadelphia, PA (US)
Filed on Oct. 24, 2023, as Appl. No. 18/492,945.
Application 18/492,945 is a continuation of application No. 17/679,356, filed on Feb. 24, 2022, granted, now 11,850,282.
Application 17/679,356 is a continuation of application No. 17/459,313, filed on Aug. 27, 2021, granted, now 11,291,716, issued on Apr. 5, 2022.
Application 17/459,313 is a continuation of application No. PCT/US2021/012630, filed on Jan. 8, 2021.
Claims priority of provisional application 63/112,219, filed on Nov. 11, 2020.
Claims priority of provisional application 63/112,202, filed on Nov. 11, 2020.
Claims priority of provisional application 63/064,506, filed on Aug. 12, 2020.
Claims priority of provisional application 63/064,571, filed on Aug. 12, 2020.
Claims priority of provisional application 62/967,104, filed on Jan. 29, 2020.
Claims priority of provisional application 62/967,242, filed on Jan. 29, 2020.
Claims priority of provisional application 62/958,809, filed on Jan. 9, 2020.
Claims priority of provisional application 62/958,827, filed on Jan. 9, 2020.
Prior Publication US 2024/0091347 A1, Mar. 21, 2024
Int. Cl. A61K 39/29 (2006.01); A61K 35/761 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61P 31/12 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01)

CPC A61K 39/292 (2013.01) [A61P 31/12 (2018.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/53 (2013.01); C12N 2710/10343 (2013.01); C12N 2730/10122 (2013.01); C12N 2730/10134 (2013.01)]

20 Claims

1. A method of inducing an immune response to HBV in a subject, the method comprising:

providing to the subject an effective amount of a first vaccine comprising a nucleic acid molecule that comprises a nucleotide sequence encoding an HBV polymerase N-terminal domain comprising the amino acid sequence of SEQ ID NO: 178 or an immunogenic fragment thereof, a nucleotide sequence encoding an HBV polymerase C-terminal domain comprising the amino acid sequence of SEQ ID NO: 179 or an immunogenic fragment thereof, and a nucleotide sequence encoding an HBV Core protein comprising the amino acid sequence of SEQ ID NO: 180 or an immunogenic fragment thereof, and

providing to the subject an effective amount of a second vaccine comprising a nucleic acid molecule that comprises a nucleotide sequence encoding an HBV polymerase N-terminal domain comprising the amino acid sequence of SEQ ID NO: 178 or an immunogenic fragment thereof, a nucleotide sequence encoding an HBV polymerase C-terminal domain comprising the amino acid sequence of SEQ ID NO: 179 or an immunogenic fragment thereof, and a nucleotide sequence encoding an HBV Core protein comprising the amino acid sequence of SEQ ID NO: 180 or an immunogenic fragment thereof,

to thereby induce an immune response to HBV.